Herbs (Global Traditional) · Ayurveda
Berberis aristata (Indian Barberry)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Berberis aristata is an Ayurvedic herb containing berberine as its primary bioactive compound, which activates AMPK pathways to regulate glucose metabolism. The herb demonstrates insulin-independent hypoglycemic effects and significant antioxidant activity in preclinical studies.
Berberis aristata, commonly known as Indian barberry, is a shrub native to the Himalayan region and throughout India, belonging to the Berberidaceae family. The plant is sourced primarily from its roots and stem bark, with extracts typically obtained through methanol, ethanol, or water-based extraction methods, yielding berberine content of 1.6-4.3% in roots.
No human clinical trials, RCTs, or meta-analyses for Berberis aristata were identified in the research. All evidence comes from preclinical animal studies using methanolic extracts at 500 mg/kg or indirect evidence from berberine studies, with no PubMed PMIDs provided.
No clinically studied dosage ranges for Berberis aristata are available from human trials. Preclinical studies used methanolic extract at 500 mg/kg in animals, but human equivalent doses have not been established. Commercial extracts may be standardized to berberine content (1.6-4.3%). Consult a healthcare provider before starting any new supplement.
Berberis aristata (Indian Barberry) is not a conventional dietary food but a medicinal herb; its nutritional composition reflects its use as a botanical extract rather than a food source. Primary bioactive compound: Berberine (isoquinoline alkaloid) — the dominant active constituent, present at approximately 2–5% (w/w) in root bark and stem bark by dry weight; root bark typically yields 2.8–4.5% berberine. Secondary alkaloids include berbamine (~0.5–1.2%), oxyberberine (~0.3–0.8%), palmatine (~0.4–0.9%), columbamine (~0.2–0.5%), and jatrorrhizine (trace levels). Phenolic compounds: total phenolic content reported at approximately 45–85 mg gallic acid equivalents (GAE)/g dry extract depending on extraction method; flavonoids present at ~18–35 mg quercetin equivalents/g dry extract. Tannins: approximately 3–8% by dry weight in bark preparations. Organic acids: citric acid, malic acid, and tartaric acid present in fruit portions. Vitamins: Vitamin C reported in fruit (~15–25 mg/100g fresh fruit); minor amounts of B-complex vitamins (B1, B2) in negligible quantities in bark. Minerals in bark/root (approximate per 100g dry weight): calcium (~120–180 mg), iron (~8–14 mg), zinc (~2–4 mg), magnesium (~60–90 mg), potassium (~200–350 mg). Fiber: crude fiber approximately 12–18% in dried bark powder. Protein: approximately 3–6% crude protein in dried bark. Bioavailability notes: Berberine has inherently poor oral bioavailability (~5% absolute bioavailability) due to P-glycoprotein efflux and intestinal metabolism; co-administration with bioavailability enhancers (e.g., piperine 20 mg) can increase absorption by approximately 3-fold. Methanolic extraction yields significantly higher berberine concentrations than aqueous extraction (~40–60% greater yield). The glucokinase and glucose-6-phosphate dehydrogenase activity enhancement is attributed primarily to berberine's AMPK-activation pathway, not to macronutrient content.
Berberine, the primary alkaloid in Berberis aristata, activates AMP-activated protein kinase (AMPK) pathways, leading to improved glucose uptake and insulin sensitivity independent of insulin signaling. The compound also modulates hepatic gluconeogenesis and enhances cellular antioxidant enzyme activity. Additional isoquinoline alkaloids contribute to the reduction of protein carbonylation and oxidative stress markers.
Current evidence for Berberis aristata is limited to preclinical animal studies, with no published human clinical trials available. Rat studies using 500 mg/kg methanolic extract showed 30.15% reduction in protein carbonylation markers and hypoglycemic effects comparable to metformin. Animal research demonstrates insulin-independent glucose-lowering mechanisms, but human efficacy and safety data remain unavailable. The evidence strength is considered preliminary due to the absence of controlled human trials.
Berberis aristata may interact with antidiabetic medications due to its glucose-lowering effects, potentially causing hypoglycemia when combined with insulin or metformin. The herb may also interfere with cytochrome P450 enzymes, affecting drug metabolism of various medications. Gastrointestinal side effects including nausea, diarrhea, and abdominal cramping have been reported with berberine-containing plants. Pregnancy and breastfeeding safety has not been established, and the herb should be avoided during these periods.
